Pan-transcriptome-based candidate therapeutic discovery for idiopathic pulmonary fibrosis

BACKGROUND: There are two US Food and Drug Administration (FDA)-approved drugs, pirfenidone and nintedanib, for treatment of patients with idiopathic pulmonary fibrosis (IPF). However, neither of these drugs provide a cure. In addition, both are associated with several drug-related adverse events. H...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Yunguan, Yella, Jaswanth K., Ghandikota, Sudhir, Cherukuri, Tejaswini C., Ediga, Harshavardhana H., Madala, Satish K., Jegga, Anil G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7659024/
https://www.ncbi.nlm.nih.gov/pubmed/33167785
http://dx.doi.org/10.1177/1753466620971143

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7659024/
https://www.ncbi.nlm.nih.gov/pubmed/33167785
http://dx.doi.org/10.1177/1753466620971143

Ejemplares similares